Hanoi 2011

ORGANISATION

________________________________________________________________________

Hanoi Meeting 2011: Presentations

November 10, Morning

Introduction to the Workshop: Explanation of the Program WBMT /WHO
Workshop

Overview of current status of Stem Cell Transplantation In Vietnam
Prof. Nguyen Anh Tri MD., PhD., Director of NIHBT

WHO AND HSC
Dr. Luc Noel, WHO Geneva

Global perspectives of HCT including networking and macroeconomics of HCT
Dietger Niederwieser, Prof. Dr. med. Dr. h.c., University of Leipzig

Blood and Marrow Transplantation in a developing country: The Philippine Experience
Honorata G. Babylon, MD, MHA, FPCP, FPSHBT

HSCT activity in Mongolia
Otgonbat A, MD, M.Sc, Department of Hematology, HSUM
Oyundelger N, MD, Clinical Professor, SCCH

Current Situation of Hematopoietic Stem Cell Transplantation in Bangladesh
Prof. M.A.Khan, MBBS,FCPS, FRCP(Edin), Department of Hematology, Dhaka Medical College & Hospital

Template Vietnam_HB Nigeria

Ngoma A., Democratic Republic of Congo

 

November 10, Afternoon

Establishing a Transplant Program

Starting a HCT program – A perspective from India
Alok Srivastava, Department of Haematology, Christian Medical College

Brazil
Adriana Seber

Starting a new Transplant Program
Weisdorf

What do we need to get started?
Hildegard Greinix, Medical University of Vienna, Austria

How to start the program
R. Suzuki

Twining and teaching
Prof. E. Holler, Dp.t of Hematology/Oncology, University Medical Center Regensburg

Education & Dissemination
Eliane Gluckman

Current Indications for HCT
J. Douglas Rizzo, MD MS

Principles of Triage in HSCT Hungarian model
Tamás Masszi, Semmelweis University, St László Hospital, Budapest, Hungary

Challenges of BMT activities in Vietnam
Tran Van Binh

Indications for Transplants and Patient Selection
WBMT/WHO Workshop

 

November 11, early Morning

Donor choice
Eliane Gluckman

„Donor suitability and donation process”
Dietger Niederwieser, Prof. Dr. med. Dr. h.c., University of Leipzig

Pedriatic Hematopoietic Stem Cell Donors: When and How can Children Ethically Donate?
Michael A. Pulsipher, MD, Associate Professor, University of Utah School of Medicine

Preregistration and five-year follow-up system for bone marrow and peripheral blood stem cell family donors – the interim report
Miyamura K, Kim S, Nagafuji K, Hino M, Suzuki R, Kodera Y,
for the Japan Society for Hematopoietc Cell Transplantation

Donor outcome follow up a global challenge
Jörg Halter, University hospital Basel, Switzerland

BM and PBSC Donor Outcomes and Recommended Follow Up
Michael A. Pulsipher, MD, Associate Professor, University of Utah School of Medicine

Protection of the Living Donor Haematopoietic Stem Cell Transplantation
Dr. Luc Noel , Coordinator “Clinical Procedures “ HSS/HDS/CPR, World Health Organization, Geneva

Legislative Frameworks and Ethics of Donation
Jeff Szer, Royal Melbourne Hospital, Australia

HLA Compatibility and Ethnicity
Yasuo Morishima MD, Aichi Cancer Center Nagoya Japan, Japan Marrow Donor Program

„Stem cell source (related/unrelated/cord blood/haploidentical)”
Dietger Niederwieser, Prof. Dr. med. Dr. h.c., Dept. Hematology, Oncology and Hemostasis/Thrombosis,
Universität Leipzig

Stem Cell Source cord blood
Shuichi Taniguchi, Department of Hematology, Toranomon Hospit

HLA mismatched/ haploidentical HSCT without in vitro T-cell depletion for the treatment of  acute leukemia
Daihong Liu, Institute of Hematology, People’s Hospital Peking University

Donor Availability: Related and Unrelated
Dennis L. Confer, MD, Chief Medical Officer National Marrow Donor Program

 

November 11, Morning

WBMT Graft Processing Workshop
Dr Mickey Koh, St George’s Hospital, London, UK, Health Sciences Authority, Singapore

Graft Processing in Japan

Hematopoietic Progenitor Cell Product Characterization
Carolyn A. Taylor, Ph.D., Professor of Medicine, Director of BMT Program Cell, Processing Laboratory

The Role of the Graft Processing Laboratory in Stem Cell Transplantation
Doug Padley, MT (ASCP), Mayo Clinic, Rochester MN USA

Graft Processing Staff, Procedures, Materials and Equipment
Ms Meng Kee TAN, Quality Management Consultant, Blood Transfusion and Medical Laboratory Services,
Canada

Cord Blood Banking
Optimising Inventories Public vs Private

Dr. Susana G Gomez, Anthony Nolan Cell Therapy Centre

Cord Blood Banking

Advanced Graft processing
Dominic Wall PhD FFSc (RCPA), Operations Director, Centre for Blood Cell Therapies, Peter MacCallum Cancer Centre

Regulatory frameworks: HSCT and other cell and tissue therapies
Srinivasan N KELLATHUR, PhD, Pharmaceuticals and Biologics Branch, Pre-market Division Health Products Regulation Group, Health Sciences Authority

Developing an Outcomes Database  Developing an Outcomes Database and Transplant Registries and Transplant Registries
Moderators: Marcelo Pasquini and Philip Rowlings

Discussion: Graft Processing Workshop

 

November 11, Afternoon

What is the minimum dataset suggested by APBMT for programs with limited resources?
Yoshiko Atsuta for the APBMT

Education & Dissemination 1
Eliane Gluckman

Dissemination of Information
David Ma

APBMT Least Minimum Data “LMD”
Dr Yoshiko Atsuta

Dissemination of Information
David Ma

World Marrow Donor Association Standards
Dennis L. Confer, MD

AABB Standards and Accreditation
Doug Padley, MT (ASCP), Mayo Clinic, Rochester MN USA

Inspection and Accreditation
Carolyn Taylor, PhD, Chair, FACT Standards Development Committee

EFI/ASHI Standards Accreditation – G. Fischer

Overview of Aide-Memoire: ‘Key elements’
Meng Kee Tan, Dr. Ineke Slaper-Cortenbach, Dr. Gottfried Fischer, Dr. Paul Eldridge and Kathy Loper, WBMT, WHO, NIHBT

Conclusions
Dennis L. Confer